GS-III · IPR · Pharma · TRIPS · Public Health · Economy
Compulsory Licensing in India — Meaning, Law & Landmark Cases ⚖️
Complete UPSC Notes — What is compulsory licensing, legal basis (TRIPS, Doha Declaration 2001), India's framework (Patents Act Sections 84, 92, 92A, 100), India's only CL (Natco vs. Bayer, 2012, Rs. 8,880/month), Section 3(d) and Novartis vs. Union of India (2013), COVID-19 TRIPS Waiver (2022), rare disease demands (SMA/Risdiplam 2024-25), global examples, PYQs, and MCQs.
⚖️ Legal basis: TRIPS Article 31 + Doha Declaration 2001
India's CL: Chapter XVI, Patents Act 1970 (Sec. 84–92A)
🇮🇳 Only CL granted: Natco vs. Bayer (Nexavar/Sorafenib) — March 9, 2012
🇮🇳 Natco price: Rs. 8,880/month vs. Bayer's Rs. ~2,80,000/month
TRIPS Waiver: WTO MC12, June 2022
SMA/Risdiplam CL demand — 2024–25
📚 Legacy IAS — Civil Services Coaching, Bangalore · Updated: April 2026 · All Facts Verified
Section 01 — Foundation
🧭 What is Compulsory Licensing? — Made Simple
💡 The "Fire Brigade Override" Analogy
Imagine a privately owned water pump that is the only one capable of fighting a massive fire threatening a whole neighbourhood. Normally, the owner has every right to use or not use it as they wish. But in an emergency, the government can commandeer the pump — the owner does NOT lose the pump, but they must allow the fire brigade to use it, and they get paid for that use. Compulsory licensing is exactly this: the government "commandeers" a patent when public need demands it. The patent holder does not lose ownership — they keep the patent and receive royalties — but they lose the exclusive right to be the only producer for the duration of the license.
📌 Definition (UPSC-Ready): A Compulsory License (CL) is an authorisation granted by the government — through the Controller of Patents — to a third party (licensee) to manufacture, use, or sell a patented product or process without the consent of the patent holder, against payment of adequate remuneration (royalty). It is an exception to the exclusive rights a patent confers and is permitted under international law (TRIPS Agreement) and India's Patents Act 1970 (Chapter XVI, Sections 84–92A). The patent owner retains ownership of the patent and receives royalties throughout.
⚠️ Key Distinction — CL is NOT the same as Patent Revocation or Patent Rejection:
• Compulsory License = patent remains valid; owner keeps it; a third party gets a licence to produce; owner gets royalties. (Example: Natco Bayer 2012 — Bayer kept Patent No. 215758)
• Patent Revocation = patent is cancelled entirely; anyone can make the product. (Not a CL.)
• Patent Rejection / Section 3(d) = patent was never granted because the invention didn't meet the threshold. (Example: Novartis Gleevec 2013 — the patent was rejected, not subject to a CL)
UPSC Mains often require distinguishing these three. The Natco case = CL. The Novartis case = Section 3(d) patent rejection. These are separate legal mechanisms serving related but distinct purposes.
The Patent Bargain
Patent law gives inventors a temporary monopoly (20 years in India) in exchange for publicly disclosing their invention. CL is the enforcement mechanism when the patent holder abuses this monopoly — by not working the invention in India, pricing it unaffordably, or not meeting public demand.
Who Grants CL in India?
The Controller General of Patents, Designs and Trade Marks (CGPDTM) — specifically through the Controller of Patents. The applicant files at the Indian Patent Office (IPO). The Controller hears both parties (patentee and applicant) before deciding.
Non-Exclusive by Default
Compulsory licences in India are non-exclusive — the original patent holder can still produce and sell their product alongside the CL holder. And they are non-assignable — the CL holder cannot transfer (sell) the licence to a third party.
Section 02 — International Framework
🌍 TRIPS, Doha Declaration & Article 31bis — The Global Architecture
📌 TRIPS Agreement (1994) — The Legal Foundation: The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), administered by the WTO, requires all member states to provide patent protection for 20 years. However, Article 31 of TRIPS explicitly permits member states to allow use of a patent without the patent holder's authorisation (compulsory licensing) subject to conditions including: adequate remuneration to the patent holder; non-exclusivity; primarily for domestic market use; and subject to judicial review.
DOHA DECLARATION 2001 — THE TURNING POINT
Doha Declaration on TRIPS and Public Health (November 14, 2001)
The WTO Ministerial Conference in Doha, Qatar (November 9–14, 2001) adopted the landmark Doha Declaration on the TRIPS Agreement and Public Health. This was triggered by the AIDS/HIV crisis in Africa — millions were dying because patented anti-retroviral drugs (ARVs) were unaffordably priced for developing nations. The Declaration made three critical clarifications:
1. Each WTO member has the right to grant compulsory licences and the freedom to determine the grounds upon which such licences are granted.
2. Each member has the right to determine what constitutes a national emergency or other circumstances of extreme urgency. Public health crises — including HIV/AIDS, tuberculosis, malaria, and other epidemics — can represent such circumstances.
3. The TRIPS Agreement "can and should be interpreted and implemented in a manner supportive of WTO Members' right to protect public health and, in particular, to promote access to medicines for all."
🎯 UPSC key: Doha Declaration did NOT amend TRIPS — it interpreted it. The actual amendment (Article 31bis) came later in 2005 (entered into force 2017). Since 2001, the TRIPS Flexibilities Database has documented 80+ instances of compulsory licensing for public health in 43 countries.
ARTICLE 31BIS — THE "PARAGRAPH 6 SYSTEM"
TRIPS Amendment — Article 31bis (2005, in force 2017)
A problem identified in the Doha Declaration: Article 31(f) of TRIPS required compulsory licences to be predominantly for the domestic market of the country granting the licence. This meant countries with no pharmaceutical manufacturing capacity (most least developed countries) could not benefit from CL in other countries — they needed to import but couldn't compel another country's CL holder to export. Paragraph 6 of the Doha Declaration tasked the TRIPS Council to find a solution. The solution: Article 31bis — a formal amendment to TRIPS allowing compulsory licences specifically for export to countries with insufficient or no pharmaceutical manufacturing capacity. India's Section 92A of the Patents Act was inserted in 2005 to implement this mechanism.
TRIPS WAIVER — COVID-19 (2022)
WTO Ministerial Conference 12 — TRIPS Waiver Decision (June 17, 2022)
In October 2020, India and South Africa jointly proposed a comprehensive waiver of TRIPS IP rights (patents, trade secrets, copyrights, industrial designs) for COVID-19 vaccines, diagnostics, and therapeutics. This was the most ambitious IP waiver proposal since Doha. After nearly two years of negotiations and intense opposition from the US, EU, and pharmaceutical industry, the WTO's 12th Ministerial Conference (MC12) in June 2022 adopted a significantly narrower Ministerial Decision — often called the "TRIPS Waiver" (though it is more accurately a "Ministerial Decision on the TRIPS Agreement"):
• Covered: COVID-19 vaccines only (NOT diagnostics or therapeutics)
• Effect: Waived the TRIPS requirement that a compulsory licence for vaccines be predominantly for the domestic market — allowing export across countries
• Duration: 5 years from June 2022
• Not covered: China was excluded from benefiting as a member. Discussions to extend to COVID-19 therapeutics and diagnostics failed to reach consensus by the December 2022 deadline.
⚠️ Critical nuance: The 2022 Decision was NOT a full suspension of patent rights — it was a clarification of existing flexibilities, primarily making the compulsory licensing mechanism for export easier to use for COVID-19 vaccines. Critics (including original India-South Africa proposal supporters) argued it fell far short of what was needed.
Section 03 — India's Legal Framework
🇮🇳 India's Compulsory Licensing Framework — Chapter XVI, Patents Act 1970
📌 Legal Basis in India: Compulsory licensing in India is governed by Chapter XVI (Sections 84 to 92A) of the Patents Act, 1970 (as amended in 2005 to incorporate TRIPS commitments). The granting authority is the Controller of Patents at the Indian Patent Office (IPO).
SECTION 84 — THE MAIN PROVISION (Applicant-Initiated)
Section 84 — Compulsory Licences on Application
Who can apply: Any person interested (including existing licensees under the patent).
When: After the expiry of 3 years from the date of grant of the patent.
Grounds (any one of three):
1. The reasonable requirements of the public with respect to the patented invention have not been satisfied
2. The patented invention is not available to the public at a reasonably affordable price
3. The patented invention is not worked in the territory of India (i.e., not manufactured in India)
Process: Applicant must first attempt to obtain a voluntary licence from the patent holder on reasonable terms (Section 84(6)) — CL is a last resort. The Controller hears both sides, considers factors including nature of invention, capability of applicant, public benefit, and reasonability of terms.
Compensation: The Controller fixes royalty rate and other terms. The CL is non-exclusive and non-assignable. Patent holder retains ownership and receives royalties.
🎯 Section 84 was the provision used in the Natco vs. Bayer (2012) case — India's first and only compulsory licence.
SECTION 92 — GOVERNMENT-INITIATED (Suo Motu)
Section 92 — Special Provision — Central Government Can Act Unilaterally
If the Central Government is satisfied that it is necessary to grant CLs in any of the following situations, it may make a declaration by notification in the Official Gazette, after which the Controller shall grant licences to applicants:
1. National Emergency
2. Circumstances of Extreme Urgency
3. Public Non-Commercial Use
Key advantage over Section 84: Under Section 92, the normal procedural requirements (including the 3-year waiting period and prior attempt at voluntary licence) are dispensed with — the licence can be granted immediately. The Controller determines a fair royalty. The word "suo motu" in the section means the Central Government can act on its own — without waiting for an applicant.
⚠️ Despite calls during the COVID-19 pandemic (2020-2021), India did NOT invoke Section 92 for COVID-19 vaccines or drugs. One reason: many COVID drug patents had not yet been granted in India; CL requires an existing valid patent. India instead used its position as a vaccine manufacturer (Serum Institute + Covishield; Bharat Biotech + Covaxin) under voluntary licensing arrangements.
SECTION 92A — FOR EXPORT
Section 92A — CL for Export to Countries Lacking Manufacturing Capacity
Inserted in 2005 to implement Article 31bis of TRIPS (Doha Paragraph 6 system). Allows CL for manufacture and export of patented pharmaceutical products to any country with insufficient or no pharmaceutical manufacturing capacity for the product concerned. The importing country must have also granted a CL or allowed importation from India (exception: LDCs not required to grant CL — only need to notify WTO Council).
SECTION 100 — GOVERNMENT USE
Section 100 — Government's Own Use of Patented Inventions
Allows the Central Government (or any person authorised by it) to use any patented invention for government purposes, even without the patent holder's consent, on payment of adequate remuneration. Unlike Sections 84 and 92, Section 100 can apply even before a patent is granted (at the application stage). In December 2024, a Rajya Sabha MP urged invocation of Section 100 for the SMA drug Risdiplam (Evrysdi by Roche) — but as of April 2026 the government has not done so.
📌 Section 3(d) — Not Compulsory Licensing, But Often Confused With It: Section 3(d) of the Patents Act is an anti-evergreening provision — it prevents patents on new forms (polymorphs, isomers, salts, esters) of a known substance unless the applicant demonstrates significantly enhanced efficacy. It means certain pharma patents are NEVER GRANTED in India. This is a patent eligibility bar — completely separate from compulsory licensing. The famous Novartis AG v. Union of India (2013) case was about Section 3(d) — the Gleevec/imatinib patent was REJECTED under Section 3(d), not subjected to a compulsory licence. This distinction is critical for UPSC.
| Feature | Section 84 (CL by applicant) | Section 92 (Govt CL) | Section 92A (Export CL) | Section 100 (Govt Use) |
|---|
| Who Initiates | Any interested person | Central Government | Any person (for export) | Central Government |
| When | After 3 years from patent grant | Any time after sealing | Any time | Any time (even pre-grant) |
| Grounds | 3 specific grounds (unaffordable, unmet demand, not worked) | National emergency, extreme urgency, public non-commercial use | Country lacks manufacturing capacity | Government purposes |
| Prior voluntary licence attempt needed? | Yes (mandatory) | No (waived) | No | No |
| Nature of Licence | Non-exclusive, non-assignable | Non-exclusive | For manufacture and export only | Government use |
| Indian Example | Natco v. Bayer (2012) — India's only CL | Never formally invoked (discussed for COVID-19) | Relevant for exporting to LDCs and nations without capacity | Proposed (not yet invoked) for Risdiplam (SMA, 2024) |
Section 04 — India's Only CL
📋 Natco Pharma vs. Bayer Corporation (2012) — India's One & Only CL
Natco Pharma Ltd. vs. Bayer Corporation — The Complete Story
The Drug: Sorafenib tosylate — sold by Bayer (Germany) under the brand name Nexavar. A targeted therapy for kidney cancer (renal cell carcinoma) and liver cancer (hepatocellular carcinoma). India's patent for sorafenib: Patent No. 215758, granted to Bayer on March 3, 2008. Bayer launched Nexavar worldwide in 2006 and in India in 2008.
The Problem: Bayer priced Nexavar at approximately Rs. 2,80,000 per month per patient (~USD 5,500/month) — unaffordable for virtually all Indian patients. In 2009, Bayer imported only around 200 bottles into India — serving approximately 200 patients — despite an estimated 8,842 kidney and liver cancer patients needing the drug in 2011 alone. Bayer had manufacturing facilities in India but chose not to manufacture Nexavar there, importing it instead.
July 29, 2011
Natco Pharma filed an application for compulsory licence under Section 84(1) of the Patents Act. Natco had previously approached Bayer for a voluntary licence — Bayer refused. The application cited all three grounds: drug not reasonably affordable, not meeting public requirements, and not being worked in India.
March 9, 2012
The Controller of Patents granted the CL to Natco Pharma — India's first ever compulsory licence. Terms: Natco must sell sorafenib at no more than Rs. 8,880 for a pack of 120 tablets (one month's treatment); pay a 6% royalty on net sales to Bayer; provide sorafenib free of charge to at least 600 "needy and deserving" patients per year; licence is non-exclusive and non-assignable; valid for the remaining patent term (until Bayer's patent expired in 2020).
2012–2013
Bayer appealed to the Intellectual Property Appellate Board (IPAB). IPAB upheld the CL but increased the royalty rate from 6% to 7% (citing Bayer's higher profit margins compared to UNDP's recommended 6% maximum). Bayer then went to the Bombay High Court.
July 15, 2014
The Bombay High Court upheld the Controller's decision granting the CL to Natco.
December 12, 2014
The Supreme Court of India dismissed Bayer's Special Leave Petition — the CL stood. India's Supreme Court kept all questions of law open but declined to interfere on the facts. The CL was fully confirmed at the highest judicial level. Bayer's 10-year patent battle effectively ended.
⚖️ Final Terms of the CL (as confirmed):
• Natco's price: Rs. 8,880 per month (~97% cheaper than Bayer's Rs. 2,80,000)
• Royalty to Bayer: 6% of net sales (Controller's original rate; IPAB increased to 7%)
• Free supply: At least 600 needy patients per year free of charge
• Nature: Non-exclusive (Bayer could still sell Nexavar), non-assignable, non-sublicensable
• Duration: For the remaining patent term (patent expired 2020; CL moot thereafter)
• Patent retained: Bayer kept Patent No. 215758 throughout
🎓 Significance & UPSC Lessons:
1. Three grounds all satisfied: Drug not worked in India (only ~200 bottles imported despite India manufacturing facilities); not reasonably affordable (Rs. 2,80,000/month vs. per capita income); not meeting public requirements (~8,842 patients, only ~200 served). This trinity of failures was the key.
2. Prior voluntary licence attempt is mandatory (Section 84(6)) — Natco approached Bayer first; Bayer refused. CL is explicitly a last resort.
3. Patent holder gets royalties — CL is not confiscation; it is compelled licensing with compensation.
4. First and ONLY CL ever granted in India under the Patents Act (as of April 2026).
5. Royalty reference: The 6% royalty was set at "the high end of the UNDP 2001 royalty guidelines" — not a figure plucked from the air.
6. Global impact: Made multinational pharmaceutical companies reconsider India pricing strategies; prompted several companies to introduce differential/tiered pricing for India proactively to avoid the CL threat.
Section 05 — The Section 3(d) Story
🔬 Novartis AG vs. Union of India (2013) — Anti-Evergreening Landmark
⚠️ Critical Distinction for UPSC: The Novartis/Gleevec case is often confused with compulsory licensing because both are about access to medicines. But they are completely different mechanisms. Natco vs. Bayer (2012) = Compulsory Licence (Section 84). Novartis vs. Union of India (2013) = Patent Rejection (Section 3(d)). In the Novartis case, no compulsory licence was ever granted — the patent itself was refused from the beginning.
Novartis AG vs. Union of India — Gleevec/Glivec (Imatinib Mesylate) — April 1, 2013
The Drug: Imatinib mesylate (beta-crystalline form) — sold as Gleevec (USA) / Glivec (India) by Novartis (Switzerland). Used to treat Chronic Myeloid Leukaemia (CML) and Gastrointestinal Stromal Tumours (GIST). Branded price in India: ~Rs. 1.2 lakh/month. Generic versions available for ~Rs. 8,000/month (1/15th the price).
The Legal Battle: Novartis applied for a patent on the beta-crystalline salt form (imatinib mesylate) — a later modification of the original imatinib compound. The Indian Patent Office rejected this in 2006 under Section 3(d) of the Patents Act — India's unique anti-evergreening provision. Novartis appealed through the IPAB and finally to the Supreme Court.
What Section 3(d) Says: "The mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance" is not patentable in India. New salts, polymorphs, esters, metabolites, or derivatives of a known drug require proof of significantly enhanced therapeutic efficacy to be patentable.
Supreme Court Decision (April 1, 2013): The SC upheld the rejection. It found that the beta-crystalline form of imatinib mesylate was a modification of the known compound imatinib (which was publicly disclosed in a 1993 Ciba-Geigy patent). Novartis did not prove that the beta-crystalline form had enhanced therapeutic efficacy compared to imatinib free base. Better physical properties (stability, lower hygroscopicity) do not equal enhanced efficacy in treating the disease.
🎓 Why It Matters for UPSC: The Novartis case established that India's Section 3(d) is a valid, WTO-compliant anti-evergreening tool. It is NOT in violation of TRIPS — TRIPS allows countries to define their own standards of patentability. India chose a higher bar for pharmaceutical patents. This means: (1) incremental modifications of existing drugs cannot be patented in India without proof of therapeutic efficacy; (2) generic versions of such drugs can be freely manufactured in India; (3) India remains the "Pharmacy of the Developing World" — producing ~20% of global generic medicine volume and supplying generic medicines to 150+ countries at 1/10th–1/30th of branded prices. This helps millions of patients globally, especially in Africa and LDCs.
Section 06 — Global Examples
🌍 Compulsory Licensing Around the World — Key Examples
| Country | Year | Drug / Technology | Ground | Outcome |
|---|
| India | 2012 |
Sorafenib tosylate (Nexavar) by Bayer — kidney & liver cancer drug |
Section 84: unaffordable price (Rs. 2,80,000/month); not worked in India; public need unmet |
CL granted to Natco at Rs. 8,880/month; 6% royalty; Supreme Court confirmed 2014. India's only CL. |
| Thailand | 2006–2008 |
Anti-retroviral drugs (Efavirenz by Merck; Lopinavir/Ritonavir by Abbott) AND heart disease drug Plavix (Clopidogrel by Sanofi-Aventis) |
Public health emergency; drugs unaffordable; government hospital patients |
Government-use CLs issued. Generic imports from India. Enabled treatment of 100,000+ HIV patients at 1/10th cost. US threatened trade sanctions (GSP withdrawal). |
| Brazil | 2007 |
Efavirenz (anti-retroviral, HIV/AIDS) by Merck |
National public interest / health emergency; Merck refused to reduce price; 75,000 patients on ARVs |
President Lula declared Efavirenz a "public interest" drug; CL issued; Brazil imported generic from India at 1/10th Merck's price. Merck eventually lowered price globally. |
| Canada | 2001 |
Cipro (Ciprofloxacin) by Bayer — anthrax treatment |
Bioterrorism threat (anthrax letters post-9/11); national emergency stockpiling |
Government threatened CL; Bayer immediately agreed to supply Cipro at reduced price — CL was not actually formally granted. Classic example of CL threat achieving price reduction. |
| USA | 2001 |
Cipro (Ciprofloxacin) by Bayer — anthrax threat |
National emergency stockpiling for anthrax bioterrorism response |
Like Canada, US threatened CL; Bayer reduced price significantly. Demonstrates that even developed countries (US is the strongest defender of IP rights) use CL threat as a bargaining tool. |
| South Africa | 2003 |
HIV/AIDS anti-retrovirals (multiple patented ARVs) |
HIV/AIDS epidemic; over 5 million South Africans HIV+; drugs unaffordable |
South Africa issued government-use authorisations for generic ARVs from India. Major pharma companies eventually dropped their patent challenges after global public pressure. Critical case that helped trigger the Doha Declaration. |
| Germany (Roche) | 1999 |
Tamiflu (Oseltamivir) — influenza/bird flu treatment |
During bird flu scare; governments needed to stockpile; Roche was sole producer |
Multiple countries threatened CLs; Roche eventually agreed to sublicense generics manufacturers worldwide to boost production. Another case of "CL threat achieving access." |
🔑 Pattern Recognition for UPSC: A key pattern across global CL use: the threat of a compulsory licence is often more effective than the CL itself. When Canada and the USA threatened to issue CLs for Cipro (anthrax threat, 2001), Bayer immediately agreed to supply at drastically reduced prices — and no formal CL was issued. Similarly, Merck reduced Efavirenz prices globally after Brazil issued a CL. This "pricing pressure" function of CL — changing patent holder behaviour without actually granting the licence — is a significant aspect of CL significance for UPSC Mains.
Section 07 — Two Sides
✅ Significance & ⚠️ Issues of Compulsory Licensing
✅ Significance — Why CL Matters
1. Access to life-saving medicines: CL reduces prices of patented drugs by 90%+ (Nexavar: Rs. 2,80,000 → Rs. 8,880; generic ARVs in Africa: $10,000/year → $150/year). For patients with life-threatening diseases in developing nations, this is the difference between life and death.
2. Bargaining leverage: The threat of a CL compels patent holders to price more reasonably. Canada and USA's Cipro threat brought Bayer to the negotiating table immediately. Brazil's Efavirenz CL prompted Merck to reduce global ARV prices.
3. Prevents patent abuse / monopoly: Patents grant 20-year monopolies in exchange for disclosure. If the patent holder refuses to manufacture in India, prices unaffordably, or ignores public need — CL corrects this abuse. It enforces the social contract underlying the patent system.
4. Pandemic preparedness: Section 92 provides a legally robust tool for governments to respond swiftly to health emergencies without prolonged court battles. During COVID-19, the availability of this tool (even if not used) was part of India's policy toolkit.
5. Supporting domestic pharmaceutical industry: CL enables Indian generic manufacturers (like Natco) to build technical capacity in producing complex patented drugs — creating industrial capability that benefits future healthcare delivery.
⚠️ Issues & Concerns
1. Disincentive to R&D: Patent protection provides the financial incentive for companies to invest billions in drug research (average cost to develop a new drug: ~$2.6 billion, 10–15 years). Frequent CLs or CL threats may discourage R&D investment — particularly for neglected tropical diseases already underserved by pharmaceutical R&D (the "Innovation Gap").
2. Quality and safety concerns: Generic manufacturers under CL may produce drugs of inferior quality without the original patent holder's manufacturing expertise, quality controls, and pharmacovigilance systems. The CL holder cannot represent that their product is identical to the original (as noted in Natco's CL terms).
3. Trade friction and diplomatic cost: India's CL for Nexavar drew strong criticism from the US pharmaceutical industry and prompted the USTR to place India on its Priority Watch List. Heavy use of CL can lead to trade retaliation, GSP withdrawal threats (Thailand), and tensions in bilateral negotiations.
4. Doesn't solve structural problems: CL addresses the patent barrier but not the other barriers to access — lack of healthcare infrastructure, cold chains, diagnostics, trained medical personnel, and distribution systems. A cheaper drug that nobody knows about or cannot reach patients does not save lives.
5. Fear of MNCs withdrawing from market: Uncertainty about the IP environment may discourage multinational pharmaceutical companies from introducing new medicines or conducting clinical trials in countries with active CL policies — reducing healthcare innovation access.
Section 08 — Current Affairs
📰 Current Affairs 2021–2026 (Fact-Verified)
🗞️ High-Priority News for UPSC 2026
JUNE 2022 — WTO MC12 TRIPS WAIVER
WTO MC12 TRIPS Waiver Decision — June 17, 2022: The WTO's 12th Ministerial Conference adopted a Ministerial Decision on the TRIPS Agreement — a limited "TRIPS Waiver" for COVID-19 vaccines. Key facts: covers
COVID-19 vaccines only (not diagnostics or therapeutics); allows eligible developing countries to produce and supply COVID-19 vaccines without patent holder consent, waiving the TRIPS requirement that CLs be predominantly for domestic market; valid for
5 years from June 2022; China excluded from benefiting. Originally proposed in October 2020 by
India and South Africa — the final agreed text was far narrower than their original proposal. Discussions to extend the waiver to COVID-19 therapeutics and diagnostics failed to reach consensus by the December 2022 deadline.
UPSC angle: India's multilateral IP diplomacy; TRIPS flexibilities; access to medicines vs. IP protection; North-South divide in global health.
NOVEMBER 2024–APRIL 2026 — RARE DISEASES
SMA (Risdiplam) — CL Demand and Section 100 Invocation Request (2024–25): Risdiplam (marketed as Evrysdi by Roche) is a patented drug for Spinal Muscular Atrophy (SMA) — a rare, progressive neuromuscular disorder. SMA affects ~1 in 7,744 live births in India; approximately 3,000–4,000 new cases annually. Risdiplam costs approximately
Rs. 6.2 lakh per bottle per month (Rs. 72 lakh per year for patients up to 20 kg) — making treatment essentially impossible for most Indian families. In
December 2024, Rajya Sabha MP Haris Beeran wrote to the Ministry of Health urging the Central Government to invoke
Section 100 of the Patents Act for local production of Risdiplam. Additionally, Natco Pharma has attempted to produce a generic version — Roche filed a lawsuit against Natco seeking an injunction. Delhi HC case ongoing. Government issued tender for procurement of 17 rare disease medicines (August 2024, Ministry of Finance).
UPSC angle: Right to health (Article 21); compulsory licensing for rare/orphan diseases; affordability vs. IP protection; Zolgensma (gene therapy for SMA) costs Rs. 14 crore — the most expensive drug in the world.
MAY 2021 — COVID-19 CL REQUESTS
CL Requests During COVID Second Wave (2021) — Not Granted: During India's devastating second COVID-19 wave (April–May 2021), multiple CL applications were filed for COVID-19 drugs.
Natco Pharma applied (May 3, 2021) for a CL for
Baricitinib (by Eli Lilly/licensed to others) — used in combination with Remdesivir for COVID-19 treatment — citing Section 92 (national emergency).
Bajaj Healthcare also applied (May 26, 2021) for Baricitinib CL. These were not granted — the government took the position that voluntary licences already existed for the drug, making national emergency grounds harder to establish.
No CL was granted for any COVID-19 drug in India. India's COVID response relied instead on: domestic vaccine manufacturing (Serum Institute producing Covishield under AstraZeneca licence; Bharat Biotech's Covaxin), compulsory waiving of import duties on medical equipment (not patents), and global vaccine diplomacy.
UPSC angle: Limits of compulsory licensing; role of voluntary licences; Section 92's conditions; India's COVID-19 pharmaceutical strategy.
DECEMBER 2025 — ADVOCACY
Calls to Invoke Section 84 for Rare Disease Drugs (December 2025): Legal experts and advocates published detailed analyses in December 2025 calling on the Indian government to invoke
Section 84 for drugs treating SMA (Risdiplam/Evrysdi by Roche), haemophilia, and thalassaemia — where patented orphan drugs cost crores annually. Arguments: (1) The drugs are not reasonably affordable (Rs. 72 lakh/year for Risdiplam vs. Indian per capita income of ~Rs. 2 lakh); (2) Not being worked in India; (3) Public requirements not being met (only a small fraction of eligible patients receive treatment). Counter-arguments: (1) Orphan diseases affect too few patients to meet Section 84's "reasonable requirements of the public" threshold; (2) CL might discourage future rare disease drug development in India; (3) Government procurement through tender may be more efficient.
UPSC angle: Expanding CL jurisprudence; right to health; rare disease policy; Section 84's applicability to orphan diseases.
INDIA'S PHARMACY OF THE WORLD ROLE — ONGOING
India as "Pharmacy of the Developing World" — IP Flexibilities in Action: India supplies approximately
20% of global generic medicine volume by volume, providing medicines to 150+ countries. Medicines for HIV/AIDS, tuberculosis, malaria, and other communicable diseases — crucial for LDCs — are produced in India at drastically reduced prices. This is possible largely because of India's strong TRIPS flexibilities framework: Section 3(d) preventing evergreening of pharma patents; compulsory licensing provisions; strong generic manufacturing base. The HIV/AIDS treatment cost has fallen from $10,000 per patient per year (2000) to approximately $150 per year — largely driven by Indian generic manufacturers.
UPSC angle: India's soft power; pharmaceutical exports; TRIPS flexibilities; right to health globally; balancing innovation incentives with access.
Section 09 — PYQs
📜 Previous Year Questions (PYQs)
🎯 UPSC PYQs — Compulsory Licensing & Related IPR
Prelims 2018
Consider: 1. TRIPS requires member states to provide product patents for pharmaceutical products. 2. LDCs have an indefinite exemption from TRIPS provisions for pharmaceuticals. 3. TRIPS prevents member states from issuing compulsory licences.
(a) 1 and 2 only (b) 2 only (c) 1 and 3 only (d) 1, 2 and 3
Answer: (a) — 1 and 2 only. Statement 3 is wrong — TRIPS Article 31 explicitly permits compulsory licensing. TRIPS does NOT prevent CLs — it sets conditions for them. This is a critical UPSC trap — the Doha Declaration (2001) further confirmed that countries have the right to grant CLs and define national emergencies. Statement 2 ✓ — LDCs have extended exemptions (currently to January 2033 or until LDC status ends). Statement 1 ✓ — TRIPS requires product and process patent protection in all technology fields including pharma (India complied by amending Patents Act in 2005).
Mains 2021 (GS-III)
"COVID-19 pandemic has highlighted the need for reconsidering the intellectual property rights (IPR) in the pharmaceutical sector. Critically examine India's position in this context."
Key points: India-South Africa TRIPS Waiver proposal (Oct 2020) — sought waiver of patents, trade secrets, copyrights, industrial designs for COVID-19 tools. WTO MC12 June 2022 adopted limited vaccine-only Ministerial Decision. India's position: strong advocate for access over exclusivity; Section 3(d) prevents evergreening; CL framework (Sections 84, 92, 92A); Covaxin (ICMR + Bharat Biotech — publicly funded IP); Covishield (licensed from AstraZeneca); India as world's largest vaccine producer (Serum Institute). Issues: no CL was actually invoked for COVID drugs; Section 92 not used; voluntary licences were relied upon instead. Balance: India's pharmaceutical exports vs. its own domestic access gaps (rare diseases, cancer drugs). Link to Doha Declaration 2001.
Mains 2016 (GS-III)
"India is a leading exporter of generic medicines. How does India's IPR regime, particularly compulsory licensing and Section 3(d), support this position?"
Key points: India = "Pharmacy of the Developing World" (20% of global generic volume by volume, 150+ countries served). CL framework: Section 84 (Natco-Bayer 2012 — only CL granted); Section 3(d) (Novartis-Gleevec 2013 — anti-evergreening). Combined effect: more medicines not patented in India → more generic production → lower prices. HIV/AIDS treatment cost fell from $10,000/year to $150/year. TRIPS Article 31 and Doha Declaration 2001 provide international backing. Issues: USTR Watch List; trade friction; R&D disincentive argument; need to balance innovation vs. access.
Mains 2019 (GS-IV Ethics)
"A pharmaceutical company has discovered a life-saving drug, but it is extremely expensive due to patented pricing. Low-income patients cannot afford it. As a healthcare policymaker, what ethical course of action would you take?" (Case Study)
Framework answer: Immediate actions: negotiate voluntary licence with patent holder (price reduction); explore if drug qualifies for Section 84 CL (3 years from patent grant, unaffordable, not working in India, demand unmet); check if Section 3(d) challenge is possible; import from countries where not patented. Medium-term: invoke Section 92 if national emergency conditions met; pursue technology transfer. Long-term: invest in domestic R&D for similar drugs; push for TRIPS reforms at WTO. Ethical frameworks: right to health (Article 21 + ICESCR); utilitarian (greatest good for greatest number — CL serves more patients); Kantian (duty of government to protect citizens; patent holder must respect societal obligations). Key balance: incentivise future innovation while ensuring current access.
Section 10 — Practice
📝 UPSC-Style MCQs — Test Yourself
Q1India's first and (as of April 2026) only compulsory licence was granted in which year, for which drug, and under which section of the Patents Act?
a) 2008; Gleevec (Imatinib) against Novartis; under Section 3(d)
b) 2012; Sorafenib tosylate (Nexavar) against Bayer; under Section 84
c) 2012; Sorafenib tosylate (Nexavar) against Bayer; under Section 92
d) 2021; Baricitinib against Eli Lilly; under Section 92
India's only compulsory licence was granted on March 9, 2012 to Natco Pharma for Sorafenib tosylate (Nexavar) — a kidney and liver cancer drug by Bayer Corporation. It was granted under Section 84 (applicant-initiated, after 3-year waiting period, on grounds of unaffordability + unmet demand + not worked in India). Section 92 was NOT used — that requires a government notification and is for national emergencies. Section 3(d) is an anti-evergreening patent bar (Novartis/Gleevec case, 2013) — a completely separate legal mechanism. Baricitinib CL requests in 2021 were filed but NOT granted. Answer: (b).
Q2Which of the following correctly describes Section 3(d) of India's Patents Act?
a) It allows the Controller to grant compulsory licences for drugs in cases of national emergency
b) It allows any person to apply for a compulsory licence after 3 years from the date of grant of a patent
c) It prevents the grant of patents on new forms of known substances unless they show significantly enhanced therapeutic efficacy — an anti-evergreening provision
d) It allows India to export patented drugs to countries with no pharmaceutical manufacturing capacity
Section 3(d) is India's unique anti-evergreening provision under the Patents Act 1970. It prevents granting patents on: new forms (polymorphs, salts, esters, isomers, derivatives) of known substances UNLESS there is proof of significantly enhanced therapeutic efficacy. Option (a) = Section 92; Option (b) = Section 84; Option (d) = Section 92A. The landmark case upholding Section 3(d) is Novartis AG v. Union of India (Supreme Court, April 1, 2013) — where Gleevec/Glivec (imatinib mesylate beta-crystalline form) patent was rejected because Novartis failed to prove enhanced therapeutic efficacy over the known imatinib compound. Answer: (c).
Q3Consider these statements about Natco Pharma's compulsory licence for Nexavar (2012):
1. The CL was granted under Section 84 of the Patents Act 1970.
2. Natco was required to pay a royalty of 6% of net sales to Bayer.
3. Natco's price for one month's treatment was capped at Rs. 8,880 (vs. Bayer's ~Rs. 2,80,000).
4. The Supreme Court of India ultimately quashed the CL in December 2014.
Which are correct?
a) 1 and 4 only
b) 2 and 3 only
c) 1, 2 and 3 only
d) 1, 2, 3 and 4
Statement 1 ✓ — Section 84(1) was the basis for Natco's application. Statement 2 ✓ — Royalty was 6% of net sales (Controller's original rate; IPAB later increased to 7%). Statement 3 ✓ — Natco's price was Rs. 8,880 for 120 tablets (one month); Bayer charged approximately Rs. 2,80,000 per month. Statement 4 ✗ — The Supreme Court on December 12, 2014 dismissed Bayer's Special Leave Petition — meaning the SC upheld the CL (did NOT quash it). The SC kept all questions of law open but did not interfere on facts. Answer: (c).
Q4Under which section of India's Patents Act can the Central Government grant compulsory licences suo motu (on its own motion) in cases of national emergency — without waiting for three years after patent grant?
a) Section 84
b) Section 92
c) Section 92A
d) Section 100
Section 92 allows the Central Government to issue a declaration in the Official Gazette at any time after sealing of the patent (no 3-year wait) in three situations: national emergency, extreme urgency, and public non-commercial use. After this declaration, the Controller grants licences to applicants. The 3-year waiting period and mandatory prior voluntary licence attempt (required under Section 84) are both waived under Section 92. Section 84 = applicant-initiated (3-year wait). Section 92A = export to countries lacking capacity. Section 100 = government use for its own purposes. Answer: (b).
Q5The Doha Declaration on the TRIPS Agreement and Public Health (2001) was significant because it:
a) Amended the TRIPS Agreement to allow compulsory licensing for the first time
b) Banned pharmaceutical patents in developing countries
c) Confirmed that each WTO member has the right to grant compulsory licences and determine what constitutes a national emergency, and that TRIPS should be interpreted in a manner supportive of access to medicines
d) Created the WTO's Dispute Settlement Mechanism for pharmaceutical patent cases
The Doha Declaration (November 14, 2001) was not a formal amendment to TRIPS — it was an interpretive declaration. It confirmed: (1) each member has the right to grant compulsory licences and the freedom to determine grounds; (2) each member has the right to define national emergency — public health crises (HIV/AIDS, TB, malaria, etc.) qualify; (3) TRIPS "can and should be interpreted" supportively of members' right to protect public health and promote access to medicines. The actual TRIPS amendment (Article 31bis) came in 2005 and entered into force in 2017 — that was about allowing export CLs. The Dispute Settlement Mechanism is a separate pre-existing WTO mechanism. Answer: (c).
Q6A key difference between the Natco vs. Bayer (2012) case and the Novartis vs. Union of India (2013) case is that:
a) Natco obtained a compulsory licence; Novartis also obtained a compulsory licence but at a lower royalty
b) Both cases involved compulsory licences, but for different drugs
c) Natco obtained a compulsory licence (Section 84) for Nexavar; in the Novartis case, no CL was involved — the Gleevec patent itself was rejected under Section 3(d)
d) Natco's case was decided by the IPAB; Novartis's case was decided by the Controller of Patents
This is a critical distinction. In Natco vs. Bayer (2012): the patent (No. 215758 for Sorafenib) was valid — Bayer kept it. Natco applied for and received a compulsory licence under Section 84 — a licence to manufacture despite the patent. In Novartis vs. Union of India (2013): there was NO compulsory licence. Novartis had applied for a patent on the beta-crystalline form of imatinib mesylate (Gleevec), and that patent application itself was rejected by the Patent Office under Section 3(d) — the anti-evergreening provision. The Supreme Court upheld this rejection. No CL was ever granted; no patent existed; generic manufacturers were already free to produce generic imatinib. These two cases are often confused but represent entirely different legal mechanisms. Answer: (c).
Q7India's Section 92A of the Patents Act (inserted in 2005) corresponds to which international instrument?
a) Article 31 of TRIPS (general compulsory licensing provisions)
b) Article 31bis of TRIPS and the Doha Declaration's Paragraph 6 — allowing compulsory licences for export to countries with no pharmaceutical manufacturing capacity
c) The 2022 WTO Ministerial Decision on TRIPS (TRIPS Waiver)
d) The Nagoya Protocol on Access and Benefit Sharing under the CBD
Section 92A was inserted in India's Patents Act in 2005 to implement the Paragraph 6 System (referred to as Article 31bis after the formal TRIPS amendment in 2005, which entered into force in 2017). Paragraph 6 of the Doha Declaration identified a problem: least developed countries (LDCs) without pharmaceutical manufacturing capacity cannot benefit from CLs because Article 31(f) of TRIPS required CLs to be predominantly for the domestic market — meaning other countries with manufacturing capacity could not produce under CL specifically for export to LDCs. Article 31bis and India's Section 92A corrected this by allowing CLs specifically for export. Answer: (b).
Section 11
🧠 Memory Aid — Lock These In
🔑 Compulsory Licensing — All Critical Facts for UPSC
DEFINITION
Government authorises a third party to produce a patented product without patent holder's consent, against payment of royalty. Patent holder retains ownership + gets royalties. India: Controller of Patents (CGPDTM) grants CL. Chapter XVI, Patents Act 1970.
NATCO CASE
India's first and only CL. Natco Pharma vs. Bayer. Drug: Sorafenib tosylate (Nexavar) — kidney & liver cancer. Section 84(1). Granted: March 9, 2012. Patent No. 215758 (granted to Bayer March 3, 2008). Natco price: Rs. 8,880/month. Bayer price: ~Rs. 2,80,000/month. Royalty: 6% (IPAB raised to 7%). 600 patients free/year. SC confirmed: Dec 12, 2014 (dismissed Bayer's SLP).
3 GROUNDS (S.84)
Any ONE of: (1) Public requirements NOT satisfied; (2) Not available at reasonably affordable price; (3) Not worked in India. Must wait 3 years from patent grant. Must first attempt voluntary licence. Natco satisfied all 3.
SEC 84 vs 92
Section 84 = applicant-initiated; 3-year wait; must try voluntary licence first. Section 92 = Central Government suo motu; no 3-year wait; grounds: national emergency / extreme urgency / public non-commercial use. Section 92 never formally invoked in India (COVID-19 discussions, not acted upon).
S.92A + S.100
Section 92A (inserted 2005) = CL for export to countries with no manufacturing capacity (Doha Paragraph 6 / Article 31bis). Section 100 = Government use for own purposes (even pre-grant); invocation sought but not used for Risdiplam (SMA, 2024).
NOVARTIS 3(d)
NOT a CL case. Section 3(d) = anti-evergreening — new forms of known substances NOT patentable without enhanced therapeutic efficacy. Gleevec (imatinib mesylate beta-crystalline) patent REJECTED (not subjected to CL). SC: April 1, 2013. Novartis vs. Union of India.
DOHA 2001
Doha Declaration on TRIPS and Public Health. November 14, 2001. Confirmed: countries can grant CLs + define national emergency. TRIPS "should be interpreted supportive of access to medicines." NOT an amendment — an interpretation. Article 31bis (formal TRIPS amendment) came in 2005 (in force 2017).
TRIPS WAIVER
WTO MC12 — June 17, 2022. Proposed by India + South Africa (Oct 2020). Final text: COVID-19 vaccines only (NOT therapeutics/diagnostics). Waived requirement that CL be for domestic market only. China excluded. 5-year duration. Narrower than original India-SA proposal.
CURRENT (2024-25)
Risdiplam (Evrysdi by Roche) for SMA: Rs. 72 lakh/year; MP urged Section 100 invocation Dec 2024; Natco attempted generic — Roche filed suit. No CL granted. Zolgensma (SMA gene therapy by Novartis) = Rs. 14 crore one-time — world's most expensive drug.
TRAPS
• CL ≠ patent revocation (patent holder keeps ownership + gets royalties). • Novartis/Gleevec = Section 3(d) REJECTION (NOT a CL). • TRIPS DOES NOT prevent CL — TRIPS Article 31 explicitly permits it. • Section 92 never invoked in India (not even for COVID). • Natco CL royalty = 6% (Controller) → 7% (IPAB on appeal). • Only ONE CL ever in India.
Section 12
❓ FAQs — Concept Clarity
Why was Section 92 not invoked during the COVID-19 pandemic in India?
Multiple factors explain why India did not invoke Section 92 during COVID-19: (1) Patent grant requirement: Compulsory licences can only be granted on patents that have actually been granted (sealed) in India. Many COVID-19 vaccine and drug patents were still pending at the Indian Patent Office or had not yet entered the national phase in India — meaning Section 92 CL would not have applied to them. (2) Voluntary licences already existed: For Baricitinib (Natco applied for CL in May 2021), voluntary licences had already been granted to other manufacturers — making the "national emergency" ground harder to establish legally. Similarly, Remdesivir was licensed voluntarily to multiple Indian generics. (3) Section 100 and procurement: India used other tools — Section 100 (government use authorisations for devices), compulsory import without patent restrictions for medical equipment, and diplomatic vaccine supply agreements. (4) India was a primary producer: Unlike LDCs, India already had the world's largest vaccine manufacturing capacity (Serum Institute produced ~1 billion Covishield doses). The bottleneck was not patents but raw materials, supply chains, and funding. The TRIPS Waiver debate was more relevant for countries without manufacturing capacity that needed to import.
Does a compulsory licence mean the original company cannot sell the drug anymore?
No — and this is a critical misconception. A compulsory licence is by default non-exclusive. In the Natco-Bayer case, Bayer continued to hold Patent No. 215758 throughout the CL period and could still sell Nexavar in India at its own price. The CL simply meant Natco could now also produce and sell a generic version at a much lower price. Bayer received 6% royalties on Natco's sales. The patent owner loses the exclusive right to be the sole producer, but does not lose ownership of the patent, the right to produce themselves, or the right to receive royalties. This is distinct from patent revocation — where the patent is cancelled entirely and nobody is exclusive. It is also distinct from patent rejection (Section 3(d)) — where the patent was never granted and generic producers were always free to produce.
What is the difference between a compulsory licence and a voluntary licence?
A voluntary licence is a freely negotiated agreement between the patent holder and a third party — the patent holder willingly grants the right to manufacture in exchange for agreed-upon royalties and terms. Both parties consent. Terms are negotiated commercially. Example: AstraZeneca voluntarily licensed Covishield to Serum Institute of India. India's pharmaceutical companies frequently enter voluntary licence agreements with multinational pharma for branded generics. A compulsory licence, by contrast, is an authorisation granted by the government (Controller of Patents) without the patent holder's consent — and against the patent holder's will. The terms (including royalty rate) are fixed by the Controller, not negotiated between parties. CL is explicitly a remedy of last resort — applicants under Section 84 must first attempt (and fail) to obtain a voluntary licence on reasonable terms before applying for a CL. The Natco case: Natco first approached Bayer for a voluntary licence; Bayer refused; only then did Natco file for a CL.
How does Section 3(d) complement compulsory licensing in India's access-to-medicines policy?
Section 3(d) and compulsory licensing are complementary but operate at different stages of the patent lifecycle. Section 3(d) is a pre-grant filter — it ensures that incremental innovations on existing drugs (new polymorphs, salts, dosage forms) do not receive patents unless they show genuinely enhanced therapeutic efficacy. This prevents "evergreening" — the practice of pharmaceutical companies extending patent monopolies through minor modifications. If Section 3(d) rejects a patent, generics can be produced freely from day one, without any CL needed. Compulsory licensing is a post-grant remedy — when a valid patent exists but the patent holder is abusing the monopoly (pricing unaffordably, not manufacturing in India, not meeting demand). Together they form India's two-tier access-to-medicines strategy: (1) First, prevent unjustified patents from being granted (Section 3(d)); (2) Second, if a valid patent exists and is being abused, allow CL (Sections 84, 92, 92A). India's pharmaceutical generic exports — supplying medicines to 150+ countries — depend heavily on both mechanisms operating together.
Section 13
🏁 Conclusion — UPSC Synthesis
⚖️ The Patent Bargain — Innovation vs. Access
A patent is a bargain: society grants an inventor a temporary monopoly to reward innovation, and in return the inventor discloses the invention so others can build upon it — and after 20 years, the invention enters the public domain. Compulsory licensing is the enforcement mechanism for this bargain: when a patent holder uses the monopoly to price a life-saving drug at Rs. 2,80,000 per month in a country where the average person earns Rs. 15,000 per month, and serves only 200 patients when tens of thousands need treatment, the bargain has broken down. India's Natco-Bayer case in 2012 was a landmark not because India frequently invokes CLs — it has granted exactly ONE in over 50 years of the Patents Act — but because it demonstrated that India is willing to use this tool when the conditions are met, and that the legal system, including the Supreme Court, will uphold it.
The emerging challenges are starker still. For rare disease drugs like Risdiplam (Rs. 72 lakh/year for SMA) or Zolgensma (Rs. 14 crore for gene therapy), the compulsory licensing framework strains at its edges — Section 84's "reasonable requirements of the public" test may be harder to satisfy for diseases affecting 1 in 7,744 births. But the right to health (Article 21 + ICESCR) does not diminish because a disease is rare. The COVID-19 TRIPS Waiver of 2022, while disappointing in its narrowness compared to the India-South Africa proposal, at least reaffirmed that the global IP system can — when pushed — prioritise human lives over patent exclusivity.
For UPSC Prelims: Only CL in India = Natco vs. Bayer (March 9, 2012); Section 84 (three grounds, 3-year wait, voluntary licence attempt first); Section 92 (government, national emergency, any time, never invoked); Section 92A (export to countries lacking capacity, Doha Paragraph 6); Section 3(d) = anti-evergreening patent REJECTION (NOT a CL — Novartis Gleevec, April 1, 2013); Natco price Rs. 8,880/month vs. Bayer Rs. ~2,80,000; 6% royalty; SC confirmed Dec 12, 2014; Doha Declaration = November 14, 2001; TRIPS Waiver = WTO MC12, June 17, 2022 (India + South Africa proposed; COVID-19 vaccines only).
For UPSC Mains: Distinguish CL, Section 3(d), patent rejection, voluntary licence clearly. Analyse Natco-Bayer with all three grounds met. Evaluate pros/cons of CL (access vs. R&D incentive vs. trade friction). Connect to COVID-19 TRIPS Waiver. Link to India's role as "Pharmacy of the Developing World." Apply ethical frameworks (right to health, utilitarian calculus, Kantian duty) from GS-IV perspective. Discuss SMA/Risdiplam as emerging frontier for CL jurisprudence.
